Ann: CLINUVEL Newsletter, page-2

"As of June 2018, 98.5% of the European EPPpatients who had received treatment during theprevious two years were continuing to receiveSCENESSE® (afamelanotide 16mg)1 in thethird annual cycle. This percentage had slightlychanged to a 95% rate of continuation andpositive feedback on treatment of 99.3%"

I don't really understand this. Maybe the "had" should be a "has" and the rate has dropped to 95% from 98.5%. 

95, 98 doesn't really matter clearly the demand remains strong from the patients, however the reluctance from payors persists due to weak study results. Will the FDA side with obvious efficacy from the EU experience or the lack of strong data from the trials? Its enough to keep you awake at night with worry!

At least we now know that the lower cash receipts announced last week was not due to patient drop out.